Bladder Cancer Progression Despite BCG Therapy Predicts Worse Outcomes
Progression on bacillus Calmette-Guérin (BCG) likely represents a biologically aggressive disease state as well as diagnostic delay, according to investigators.
Immunotherapy
OAB Symptoms Increase With Longer BCG Therapy for NMIBC
Intravesical BCG therapy is effective in treating NMIBC, but it comes with side effects such as overactive bladder.
First-Line Immunotherapy, Chemotherapy for mUC of the Bladder Offer Similar Survival
Real-world data validate recently reported findings from clinical trials.
Biomarkers Identify Immune Checkpoint Inhibitor-Related Acute Kidney Injury
Prompt diagnosis of AKI and the ability to rule out immune checkpoint inhibitors as the cause may allow patients to continue with cancer immunotherapy.
Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...